DK3078372T3 - Terapeutisk middel mod sygdom på basis af hæmmende virkning af makrofag-migrationshæmmende faktor - Google Patents
Terapeutisk middel mod sygdom på basis af hæmmende virkning af makrofag-migrationshæmmende faktor Download PDFInfo
- Publication number
- DK3078372T3 DK3078372T3 DK16169414.6T DK16169414T DK3078372T3 DK 3078372 T3 DK3078372 T3 DK 3078372T3 DK 16169414 T DK16169414 T DK 16169414T DK 3078372 T3 DK3078372 T3 DK 3078372T3
- Authority
- DK
- Denmark
- Prior art keywords
- benzopyran
- oxo
- phenoxy
- amino
- pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Claims (9)
1. Benzopyranderivat til anvendelse ved behandling af neuropatisk smerte, hvor benzopyranderivatet er repræsenteret af den følgende almene formel, eller et salt deraf, Formel I
hvor R1 repræsenterer en eventuelt substitueret Ci-6-alkylgruppe; en af R2 og R3 repræsenterer et hydrogenatom; og den anden af R2 og R3 repræsenterer et hydrogenatom, en eventuelt substitueret aminogruppe, en eventuelt substitueret acylaminogruppe, en eventuelt substitueret cabamoylgruppe eller en eventuelt substitueret arylgruppe.
2. Benzopyranderivat til anvendelse ifølge krav 1, hvor en af R2 og R3 repræsenterer et hydrogenatom; og den anden af R2 og R3 repræsenterer en eventuelt substitueret acylaminogruppe.
3. Benzopyranderivat til anvendelse ifølge krav 1, hvor benzopyranderivatet er N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]for-mamid, N-(3-amino-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)methansulfon-amid, N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]-acetamid, N-(4-oxo-6-phenoxy-4H-1 -benzopyran-7-yl)methansulfonamid, 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-2-carboxamid, N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-2-yl]acetamid, 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-carboxamid, N-[7-[(ethylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]formamid eller N-(4-oxo-6-phenoxy-2-phenyl-4H-1-benzopyran-7-yl)methansulfonamid.
4. Benzopyranderivat til anvendelse ifølge krav 1, hvor benzopyranderivatet er N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]for-mamid.
5. Behandlingsmiddel til anvendelse ved behandling af neuropatisk smerte, hvor behandlingsmidlet omfatter et benzopyranderivat repræsenteret ved den følgende formel, eller et salt deraf, Formel 2
hvor R1 repræsenterer en eventuelt substitueret Ci-6-alkylgruppe; en af R2 og R3 repræsenterer et hydrogenatom; og den anden af R2 og R3 repræsenterer et hydrogenatom, en eventuelt substitueret aminogruppe, en eventuelt substitueret acylaminogruppe, en eventuelt substitueret cabamoylgruppe eller en eventuelt substitueret arylgruppe.
6. Behandlingsmiddel til anvendelse ifølge krav 5, hvor en af R2 og R3 repræsenterer et hydrogenatom; og den anden af R2 og R3 repræsenterer en eventuelt substitueret acylaminogruppe.
7. Behandlingsmiddel til anvendelse ifølge krav 5, hvor benzopyranderivatet er N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]for-mamid, N-(3-amino-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)methansulfon-amid, N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]-acetamid, N-(4-oxo-6-phenoxy-4H-1 -benzopyran-7-yl)methansulfonamid, 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-2-carboxamid, N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-2-yl]acetamid, 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-carboxamid, N-[7-[(ethylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]formamid eller N-(4-oxo-6-phenoxy-2-phenyl-4H-1-benzopyran-7-yl)methansulfonamid.
8. Behandlingsmiddel til anvendelse ifølge krav 5, hvor benzopyranderivatet er N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]for- mamid.
9. Behandlingsmiddel til anvendelse ifølge et af kravene 5 til 8, hvor den neu-ropatiske smerte er fibromyalgi, postherpetisk smerte, diabetisk neuropati, smerter relateret til post-rygmarvsskade, postapoplektisk smerte, kronisk smerte, komplekst regionalt smertesyndrom, rygsmerter, som NSAID'er ikke er tilstrækkeligt virksomme for, ischias, bækkenbundssmerter, trigeminal neuralgi, osteoarthritis-smerter, som NSAID'er ikke er tilstrækkeligt virksomme for, deafferenterings-smertesyndrom, smerte forårsaget af myositis, smerte forårsaget af fasciitis, og smerte forårsaget af seronegativ arthritis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013149690 | 2013-07-18 | ||
| EP14826811.3A EP2929880B1 (en) | 2013-07-18 | 2014-07-17 | Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3078372T3 true DK3078372T3 (da) | 2017-10-16 |
Family
ID=52346269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16169414.6T DK3078372T3 (da) | 2013-07-18 | 2014-07-17 | Terapeutisk middel mod sygdom på basis af hæmmende virkning af makrofag-migrationshæmmende faktor |
| DK14826811.3T DK2929880T3 (da) | 2013-07-18 | 2014-07-17 | Terapeutisk middel til sygdom baseret på hæmmende effekt af makrofag-migrationshæmmende faktor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14826811.3T DK2929880T3 (da) | 2013-07-18 | 2014-07-17 | Terapeutisk middel til sygdom baseret på hæmmende effekt af makrofag-migrationshæmmende faktor |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20150353519A1 (da) |
| EP (2) | EP3078372B1 (da) |
| JP (2) | JP5802868B2 (da) |
| CN (1) | CN105407887B (da) |
| AU (1) | AU2014291149B2 (da) |
| CA (1) | CA2918325C (da) |
| CY (2) | CY1118140T1 (da) |
| DK (2) | DK3078372T3 (da) |
| ES (2) | ES2593527T3 (da) |
| HK (1) | HK1222556A1 (da) |
| HR (2) | HRP20161317T1 (da) |
| HU (2) | HUE029800T2 (da) |
| IL (1) | IL243550B (da) |
| LT (2) | LT2929880T (da) |
| NO (1) | NO3078372T3 (da) |
| PL (2) | PL3078372T3 (da) |
| PT (2) | PT2929880T (da) |
| RS (2) | RS56489B1 (da) |
| RU (2) | RU2750540C2 (da) |
| SI (2) | SI3078372T1 (da) |
| SM (1) | SMT201700080B (da) |
| TW (1) | TWI603965B (da) |
| WO (1) | WO2015008827A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018137708A1 (zh) * | 2017-01-26 | 2018-08-02 | 重庆莱美药业股份有限公司 | 一种纳米炭-铁复合体系及其组合物、制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0753725B2 (ja) * | 1987-10-08 | 1995-06-07 | 富山化学工業株式会社 | ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤 |
| ES2160626T3 (es) * | 1993-04-09 | 2001-11-16 | Toyama Chemical Co Ltd | Inmunomodulador, inhibidor de la adherencia celular, y agente que permite tratar y prevenir enfermedades autoinmunes. |
| WO1997023714A1 (de) * | 1995-12-21 | 1997-07-03 | Siemens Aktiengesellschaft | Luftansaugvorrichtung mit variabler saugrohrlänge für eine brennkraftmaschine |
| DE10044091A1 (de) * | 2000-09-07 | 2002-04-04 | Merck Patent Gmbh | Chromanonderivate |
| GB0507695D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| GB0507696D0 (en) * | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| WO2007042035A2 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| CN103826624A (zh) | 2011-08-30 | 2014-05-28 | 富山化学工业株式会社 | 类风湿性关节炎等自身免疫疾病的处置的改善方法 |
-
2014
- 2014-07-17 CA CA2918325A patent/CA2918325C/en active Active
- 2014-07-17 RU RU2017131951A patent/RU2750540C2/ru active
- 2014-07-17 PL PL16169414T patent/PL3078372T3/pl unknown
- 2014-07-17 DK DK16169414.6T patent/DK3078372T3/da active
- 2014-07-17 RS RS20171061A patent/RS56489B1/sr unknown
- 2014-07-17 WO PCT/JP2014/069026 patent/WO2015008827A1/ja active Application Filing
- 2014-07-17 HU HUE14826811A patent/HUE029800T2/en unknown
- 2014-07-17 EP EP16169414.6A patent/EP3078372B1/en active Active
- 2014-07-17 HU HUE16169414A patent/HUE034661T2/en unknown
- 2014-07-17 ES ES14826811.3T patent/ES2593527T3/es active Active
- 2014-07-17 SI SI201430469T patent/SI3078372T1/en unknown
- 2014-07-17 LT LTEP14826811.3T patent/LT2929880T/lt unknown
- 2014-07-17 SI SI201430088A patent/SI2929880T1/sl unknown
- 2014-07-17 AU AU2014291149A patent/AU2014291149B2/en active Active
- 2014-07-17 PL PL14826811T patent/PL2929880T3/pl unknown
- 2014-07-17 PT PT148268113T patent/PT2929880T/pt unknown
- 2014-07-17 EP EP14826811.3A patent/EP2929880B1/en active Active
- 2014-07-17 JP JP2015527333A patent/JP5802868B2/ja active Active
- 2014-07-17 DK DK14826811.3T patent/DK2929880T3/da active
- 2014-07-17 ES ES16169414.6T patent/ES2642440T3/es active Active
- 2014-07-17 LT LTEP16169414.6T patent/LT3078372T/lt unknown
- 2014-07-17 US US14/647,931 patent/US20150353519A1/en not_active Abandoned
- 2014-07-17 CN CN201480040609.XA patent/CN105407887B/zh active Active
- 2014-07-17 PT PT161694146T patent/PT3078372T/pt unknown
- 2014-07-17 RU RU2016105141A patent/RU2641301C2/ru active
- 2014-07-17 NO NO16169414A patent/NO3078372T3/no unknown
- 2014-07-17 RS RS20161048A patent/RS55394B1/sr unknown
- 2014-07-18 TW TW103124716A patent/TWI603965B/zh active
-
2015
- 2015-08-27 JP JP2015167851A patent/JP6060231B2/ja active Active
-
2016
- 2016-01-11 IL IL243550A patent/IL243550B/en active IP Right Grant
- 2016-04-19 US US15/132,892 patent/US9918963B2/en active Active
- 2016-04-19 US US15/132,981 patent/US20160228406A1/en not_active Abandoned
- 2016-09-09 HK HK16110748.6A patent/HK1222556A1/zh unknown
- 2016-10-11 HR HRP20161317TT patent/HRP20161317T1/hr unknown
- 2016-10-25 CY CY20161101077T patent/CY1118140T1/el unknown
-
2017
- 2017-02-03 SM SM201700080T patent/SMT201700080B/it unknown
- 2017-09-26 CY CY20171101008T patent/CY1119496T1/el unknown
- 2017-10-05 HR HRP20171497TT patent/HRP20171497T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7301741B2 (ja) | 補体活性のモジュレータ | |
| CN105378159A (zh) | 调节血清低密度脂蛋白（LDL）水平的前蛋白转化酶枯草杆菌蛋白酶/Kexin 9 型（PCSK9）变构结合配体 | |
| JP2007501775A (ja) | 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤 | |
| ES2355768T3 (es) | Potenciador de la actividad de la proteína quinasa c que contiene un derivado de éter de alquilo o una sal del mismo. | |
| BR112020025018A2 (pt) | compostos para inibição de inflamação | |
| KR102144323B1 (ko) | 글루타티온 다이설파이드 및 글루타티온 다이설파이드 s-옥사이드를 포함한 제약학적 조성물 | |
| JP5913651B2 (ja) | 疼痛および他の疾患の処置のための化合物および方法 | |
| TW201803562A (zh) | 用於纖維化之治療之wnt抑制劑 | |
| TW202106290A (zh) | 用於調節補體活性之組成物及方法 | |
| DK3078372T3 (da) | Terapeutisk middel mod sygdom på basis af hæmmende virkning af makrofag-migrationshæmmende faktor | |
| Wang et al. | Osteoclasts and osteoarthritis: Novel intervention targets and therapeutic potentials during aging | |
| EP2338908A1 (fr) | Peptides comportant des modifications de type post-translationnel et leur utilisation dans le cadre du traitement de pathologies auto-immunes | |
| RU2799049C2 (ru) | Способы лечения изменений поведения | |
| BR112021012449A2 (pt) | Agente para promoção da função de advilina, derivado de amina cíclica, e, medicamento |